{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T10:37:22Z","timestamp":1793356642397,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T00:00:00Z","timestamp":1705968000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005339","name":"American Academy of Neurology","doi-asserted-by":"publisher","award":["P11.006"],"award-info":[{"award-number":["P11.006"]}],"id":[{"id":"10.13039\/100005339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018439","name":"SK Life Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018439","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.eplepsyres.2024.107306","type":"journal-article","created":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T11:39:17Z","timestamp":1705923557000},"page":"107306","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Reductions in concomitant antiseizure medication drug load during adjunctive cenobamate therapy: Post-hoc analysis of a subset of patients from a phase 3, multicenter, open-label study"],"prefix":"10.1016","volume":"200","author":[{"given":"Sami","family":"Aboumatar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Stern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarence T.","family":"Wade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mindl","family":"Weingarten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory S.","family":"Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William E.","family":"Rosenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eplepsyres.2024.107306_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2022.106952","article-title":"Efficacy of cenobamate for uncontrolled focal seizures in patients with previous epilepsy-related surgery: Post hoc analysis of a phase 3, multicenter, open-label study","volume":"184","author":"Abou-Khalil","year":"2022","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2024.107306_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2022.107014","article-title":"Post hoc analysis of a phase 3 study for treatment of uncontrolled focal seizures: adjunctive cenobamate dose and seizure reduction by baseline seizure frequency","volume":"186","author":"Aboumatar","year":"2022","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2024.107306_bib3","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.yebeh.2017.11.006","article-title":"Quality of life in adults with epilepsy is associated with anticonvulsant polypharmacy independent of seizure status","volume":"78","author":"Alexander","year":"2018","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2024.107306_bib4","series-title":"Ontozry [Summary of Product Characteristics]","author":"Angelini Pharma","year":"2023"},{"key":"10.1016\/j.eplepsyres.2024.107306_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2023.107242","article-title":"Dose reduction and discontinuation of concomitant antiseizure medications after initiating cenobamate: a retrospective review","volume":"197","author":"Becker","year":"2023","journal-title":"Epilepsy Res."},{"issue":"5","key":"10.1016\/j.eplepsyres.2024.107306_bib6","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/j.1528-1167.2010.02520.x","article-title":"Relationship between adverse effects of antiepileptic drugs, number of coprescribed drugs, and drug load in a large cohort of consecutive patients with drug-refractory epilepsy","volume":"51","author":"Canevini","year":"2010","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.eplepsyres.2024.107306_bib7","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1001\/jamaneurol.2017.3949","article-title":"Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-year longitudinal cohort study","volume":"75","author":"Chen","year":"2018","journal-title":"JAMA Neurol."},{"issue":"22","key":"10.1016\/j.eplepsyres.2024.107306_bib8","doi-asserted-by":"crossref","first-page":"e2311","DOI":"10.1212\/WNL.0000000000009530","article-title":"Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures","volume":"94","author":"Chung","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2024.107306_bib9","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.seizure.2015.02.025","article-title":"Effect of reduction of antiepileptic drugs in patients with drug-refractory epilepsy","volume":"27","author":"Dash","year":"2015","journal-title":"Seizure"},{"issue":"5","key":"10.1016\/j.eplepsyres.2024.107306_bib10","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/j.1528-1157.1997.tb01142.x","article-title":"Reappraisal of polytherapy in epilepsy: a critical review of drug load and adverse effects","volume":"38","author":"Deckers","year":"1997","journal-title":"Epilepsia"},{"issue":"10","key":"10.1016\/j.eplepsyres.2024.107306_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2022.e11073","article-title":"Anti-seizure medications and quality of life in person with epilepsy","volume":"8","author":"Dwivedi","year":"2022","journal-title":"Heliyon"},{"key":"10.1016\/j.eplepsyres.2024.107306_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.107796","article-title":"Cenobamate treatment of focal-onset seizures: quality of life and outcome during up to eight years of treatment","volume":"116","author":"Elizebath","year":"2021","journal-title":"Epilepsy Behav."},{"issue":"4","key":"10.1016\/j.eplepsyres.2024.107306_bib13","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1111\/cts.13204","article-title":"Effect of cenobamate on the single-dose pharmacokinetics of multiple cytochrome P450 probes using a cocktail approach in healthy subjects","volume":"15","author":"Greene","year":"2022","journal-title":"Clin. Transl. Sci."},{"issue":"2","key":"10.1016\/j.eplepsyres.2024.107306_bib14","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s40801-016-0077-2","article-title":"Systematic adverse drug reaction monitoring of patients under newer antiepileptic drugs using routine clinical data of inpatients","volume":"3","author":"Hilgers","year":"2016","journal-title":"Drugs Real. World Outcomes"},{"issue":"3","key":"10.1016\/j.eplepsyres.2024.107306_bib15","doi-asserted-by":"crossref","first-page":"317","DOI":"10.4103\/ijmr.IJMR_710_15","article-title":"Adverse effects & drug load of antiepileptic drugs in patients with epilepsy: monotherapy versus polytherapy","volume":"145","author":"Joshi","year":"2017","journal-title":"Indian J. Med Res."},{"issue":"10","key":"10.1016\/j.eplepsyres.2024.107306_bib16","doi-asserted-by":"crossref","first-page":"e989","DOI":"10.1212\/WNL.0000000000200792","article-title":"Long-term efficacy and safety from an open-label extension of adjunctive cenobamate in patients with uncontrolled focal seizures","volume":"99","author":"Klein","year":"2022","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.eplepsyres.2024.107306_bib17","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S1474-4422(19)30399-0","article-title":"Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial","volume":"19","author":"Krauss","year":"2020","journal-title":"Lancet Neurol."},{"issue":"7","key":"10.1016\/j.eplepsyres.2024.107306_bib18","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1053\/seiz.2000.0442","article-title":"Epilepsy after the first drug fails: substitution or add-on?","volume":"9","author":"Kwan","year":"2000","journal-title":"Seizure"},{"issue":"6","key":"10.1016\/j.eplepsyres.2024.107306_bib19","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","article-title":"Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies","volume":"51","author":"Kwan","year":"2010","journal-title":"Epilepsia"},{"issue":"11","key":"10.1016\/j.eplepsyres.2024.107306_bib20","doi-asserted-by":"crossref","DOI":"10.1007\/s11910-016-0696-8","article-title":"Treatment of epilepsy in the elderly","volume":"16","author":"Motika","year":"2016","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"10.1016\/j.eplepsyres.2024.107306_bib21","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/2806341","article-title":"Medication belief and adherence among patients with epilepsy","volume":"2019","author":"Niriayo","year":"2019","journal-title":"Behav. Neurol."},{"issue":"11","key":"10.1016\/j.eplepsyres.2024.107306_bib22","doi-asserted-by":"crossref","first-page":"897","DOI":"10.2165\/00023210-200519110-00001","article-title":"Overtreatment in epilepsy: how it occurs and how it can be avoided","volume":"19","author":"Perucca","year":"2005","journal-title":"CNS Drugs"},{"issue":"suppl 1","key":"10.1016\/j.eplepsyres.2024.107306_bib23","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/j.eplepsyres.2005.07.017","article-title":"Pharmacological and clinical aspects of antiepileptic drug use in the elderly","volume":"68","author":"Perucca","year":"2006","journal-title":"Epilepsy Res"},{"issue":"3","key":"10.1016\/j.eplepsyres.2024.107306_bib24","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.yebeh.2004.01.006","article-title":"Improvement in seizure control and quality of life in medically refractory epilepsy patients converted from polypharmacy to monotherapy","volume":"5","author":"Pirio Richardson","year":"2004","journal-title":"Epilepsy Behav."},{"issue":"Pt A","key":"10.1016\/j.eplepsyres.2024.107306_bib25","article-title":"Treatment-emergent adverse events and antiseizure medication actual drug load","volume":"137","author":"Pr\u00e9tat","year":"2022","journal-title":"Epilepsy Behav."},{"issue":"3","key":"10.1016\/j.eplepsyres.2024.107306_bib26","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/epi4.12346","article-title":"Changes in drug load during lacosamide combination therapy: a noninterventional, observational study in German and Austrian clinical practice","volume":"4","author":"Reinhardt","year":"2019","journal-title":"Epilepsia Open"},{"issue":"10","key":"10.1016\/j.eplepsyres.2024.107306_bib27","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1080\/17425255.2020.1806236","article-title":"Pharmacokinetic considerations about antiseizure medications in the elderly","volume":"16","author":"Roberti","year":"2020","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"12","key":"10.1016\/j.eplepsyres.2024.107306_bib28","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1111\/epi.17092","article-title":"Post-hoc analysis of a phase 3, multicenter, open-label study of cenobamate for treatment of uncontrolled focal seizures: effects of dose adjustments of concomitant antiseizure medications","volume":"62","author":"Rosenfeld","year":"2021","journal-title":"Epilepsia"},{"issue":"4","key":"10.1016\/j.eplepsyres.2024.107306_bib29","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1055\/s-0040-1715991","article-title":"Simultaneous use of two different tools to assess compliance with antiepileptic drugs: experience in a community-based study","volume":"11","author":"Singh","year":"2020","journal-title":"J. Neurosci. Rural Pract."},{"key":"10.1016\/j.eplepsyres.2024.107306_bib30","series-title":"XCOPRI\u00ae (cEnobamate Tablets), for Oral Use, CV [Prescribing Information]","year":"2022"},{"key":"10.1016\/j.eplepsyres.2024.107306_bib31","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1007\/s40120-022-00400-5","article-title":"Dose adjustment of concomitant antiseizure medications during cenobamate treatment: expert opinion consensus recommendations","volume":"11","author":"Smith","year":"2022","journal-title":"Neurol. Ther."},{"issue":"6","key":"10.1016\/j.eplepsyres.2024.107306_bib32","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1111\/epi.16525","article-title":"Cenobamate (YKP3089) as adjunctive treatment for uncontrolled focal seizures in a large, phase 3, multicenter, open-label safety study","volume":"61","author":"Sperling","year":"2020","journal-title":"Epilepsia"},{"issue":"12","key":"10.1016\/j.eplepsyres.2024.107306_bib33","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1111\/epi.17091","article-title":"Efficacy of cenobamate for uncontrolled focal seizures: post-hoc analysis of a phase 3, multicenter, open-label study","volume":"62","author":"Sperling","year":"2021","journal-title":"Epilepsia"},{"issue":"2","key":"10.1016\/j.eplepsyres.2024.107306_bib34","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2174\/157015909788848866","article-title":"Antiepileptic drug monotherapy: the initial approach in epilepsy management","volume":"7","author":"St. Louis","year":"2009","journal-title":"Curr. Neuropharmacol."},{"issue":"17","key":"10.1016\/j.eplepsyres.2024.107306_bib35","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1212\/WNL.0000000000011839","article-title":"Incidence and prevalence of drug-resistant epilepsy: a systematic review and meta-analysis","volume":"96","author":"Sultana","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2024.107306_bib36","series-title":"Vimpat 50mg,100mg, 150mg, 200mg Film-coated Tablets [Summary of Product Characteristics]","author":"UCB Pharma","year":"2022"},{"key":"10.1016\/j.eplepsyres.2024.107306_bib37","unstructured":"WHO Collaborating Centre for Drug Statistics, 2023. WHO Collaborating Centre for Drug Statistics. ATC\/DDD index 2023. \u3008https:\/\/www.whocc.no\/atc_ddd_index\/\u3009 (Accessed 21 April 2023)."},{"issue":"11","key":"10.1016\/j.eplepsyres.2024.107306_bib38","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1016\/j.euroneuro.2015.07.027","article-title":"Adverse cognitive effects of antiepileptic pharmacotherapy: each additional drug matters","volume":"25","author":"Witt","year":"2015","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"12","key":"10.1016\/j.eplepsyres.2024.107306_bib39","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1111\/epi.16720","article-title":"Does the accumulated antiepileptic drug load in chronic epilepsy reflect disease severity?","volume":"61","author":"Witt","year":"2020","journal-title":"Epilepsia"}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121124000214?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121124000214?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T22:16:51Z","timestamp":1736201811000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920121124000214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":39,"alternative-id":["S0920121124000214"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2024.107306","relation":{},"ISSN":["0920-1211"],"issn-type":[{"value":"0920-1211","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reductions in concomitant antiseizure medication drug load during adjunctive cenobamate therapy: Post-hoc analysis of a subset of patients from a phase 3, multicenter, open-label study","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2024.107306","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107306"}}